504
Participants
Start Date
February 28, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2026
Benralizumab
Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.
Research Site, Hohhot
Research Site, Shijiazhuang
Research Site, Tangshan
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Shenyang
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Nanjing
Research Site, Suzhou
Research Site, Suzhou
Research Site, Xuzhou
Research Site, Yangzhou
Research Site, Hefei
Research Site, Hefei
Research Site, Wuhu
Research Site, Jinan
Research Site, Jinan
Research Site, Jinan
Research Site, Weifang
Research Site, Qingdao
Research Site, Tianjin
Research Site, Tianjin
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Huzhou
Research Site, Ningbo
Research Site, Wenzhou
Research Site, Xiamen
Research Site, Zhangzhou
Research Site, Chongqing
Research Site, Changsha
Research Site, Changsha
Research Site, Changsha
Research Site, Wuhan
Research Site, Wuhan
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Zhengzhou
Research Site, Zhengzhou
Research Site, Xinxiang
Research Site, Luoyang
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guiyang
Research Site, Shenzhen
Research Site, Shenzhen
Research Site, Shenzhen
Research Site, Shenzhen
Research Site, Nanning
Research Site, Guilin
Research Site, Chengdu
Research Site, Chengdu
Research Site, Chengdu
Research Site, Chengdu
Research Site, Xi'an
Research Site, Xi'an
Research Site, Xi'an
Research Site, Lanzhou
Research Site, Hohhot
Research Site, Kunming
Research Site, Shenyang
Research Site, Shijiazhuang
Research Site, Taiyuan
Research Site, Taiyuan
Lead Sponsor
AstraZeneca
INDUSTRY